Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib / II Study of Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer

NCT05035914 is registered in ClinicalTrials.gov with Guangzhou University of Traditional Chinese Medicine as lead sponsor.

NCT NCT05035914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05035914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib / II Study of Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer
Lead sponsor
Guangzhou University of Traditional Chinese Medicine
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 9, 2021
Completion date
December 31, 2024
Enrollment
94 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer